USPTO hands win to Daiichi Sankyo in cancer drug dispute – Life Sciences IP Review

18th January 2024

Daiichi Sankyo secures nearly $46m legal fees in antibody arbitration 30-11-2023 · Daiichi Sankyo unit accuses Pharmacosmos of patent infringement 12- …